A unique system that can sensitively assess the risk of chemical leukoderma by using murine tail skin
A unique system that can sensitively assess the risk of chemical leukoderma by using murine tail skin
复制标题
DOI：
10.1016/j.chemosphere.2019.06.185
复制
发表时间：
2019-11-01
期刊：
影响因子：
8.8
通讯作者：
Kato, Masashi
中科院分区：
文献类型：
--
作者：
Iida, Machiko;Tazaki, Akira;Kato, Masashi
化学性白细胞增多症是皮肤上的斑片状色素减退。据报道，苯酚衍生物（如乌藨子酮）可导致职业性白血病的发生。最近，2%（w/w）的杜鹃烯醇，一种用于皮肤闪电剂的乌藨子酮的还原形式，也导致了包括日本在内的亚洲国家> 16，000名用户（约占所有用户的2%）的白细胞增多症。然而，尽管先前在动物实验中显示了由30%杜鹃烯醇引起的白血病的发展，但尚未建立用于评估由2%杜鹃烯醇引起的白血病风险的方法。需要建立一种新的技术来评估由化学品外部治疗引起的人类白血病的风险，以防止未来可能发生的化学灾难。该研究表明，用2%的杜鹃烯醇和相同浓度的乌藨子酮进行外部处理，无一例外地导致小鼠尾部皮肤中白细胞增多，表皮中黑色素的量和黑色素细胞的数量显著减少。因此，开发了一种新的体内技术，可以评估由2%杜鹃烯醇引起的白血病的风险。利用尾巴皮肤的独特技术有可能在未来预防化学性白血病。(C)2019爱思唯尔有限公司版权所有。
Chemical leukoderma is a patchy hypopigmentation in the skin. Phenol derivatives such as raspberry ketone have been reported to cause the development of occupationally induced leukoderma. Recently, 2% (w/w) rhododenol, a reduced form of raspberry ketone used in a skin-lightning agent, also caused the development of leukoderma in >16,000 users, about 2% of all users, in Asian countries including Japan. However, a method for assessing the risk of leukoderma caused by 2% rhododenol has not been established despite the fact that the development of leukoderma caused by 30% rhododenol was previously shown in animal experiments. Establishment of a novel technique for risk assessment of leukoderma in humans caused by external treatment with chemicals is needed to prevent a possible future chemical disaster. This study demonstrated that external treatment with 2% rhododenol and the same concentration of raspberry ketone caused the development of leukoderma in murine tail skin without exception with significant decreases in the amount of melanin and number of melanocytes in the epidermis. Thus, a novel in vivo technique that can assess the risk of leukoderma caused by 2% rhododenol was developed. The unique technique using tail skin has the potential to prevent chemical leukoderma in the future. (C) 2019 Elsevier Ltd. All rights reserved.